Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Akorn Inc. -- Ignore unavailable to you. Want to Upgrade?

To: John Metcalf who wrote (98)	8/28/2000 2:08:06 PM
From: Czechsinthemail	Respond to of 101

John, Thanks for the heads up. There is a good chance that the BOL announcements are behind the recent run in AKRN. However, should BOL decide to sell their business, it might be picked up by an equally aggressive competitor. Meanwhile, I think there are some real concerns around the high competition and low margins. AKRN's recent quarters have been underwhelming. Their growth has been more modest than eye-opening. Some of that is no doubt coming from higher expenses related to clinical trials. We may see further weakness around expectations of a weak Sep quarter.